港股異動 | 賽生藥業(6600.HK)漲4.1% 2021年淨利增加22% 獲許購回最多約6778.74萬股股份
格隆匯3月25日丨賽生藥業(6600.HK)漲4.1%,報7.87港元,總市值53億港元。該公司昨日發佈財報,截至2021年12月31日止年度,收入約為人民幣25.18億元,較去年增長約31.3%,創過往四年的增長新高,乃受自有產品日達仙的強勁銷售及授權引入產品開始銷售所帶動;淨利潤約為人民幣9.23億元,較去年增加約22.5%;公司擁有人應占每股基本盈利約為人民幣1.42元,較去年同期增加約2.9%;公司擁有人應占每股攤薄盈利約為人民幣1.33元,較去年同期減少約1.5%。該公司董事會已批准行使購回公司股份的一般授權的計劃。根據股份購回授權,公司獲許購回最多6778.74萬股股份,佔公司於股東周年大會當日於聯交所已發行股份總數的10%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.